Neurocrine (NBIX) director Stephen Sherwin receives 2,567 RSU equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.

NEUROCRINE BIOSCIENCES INC director Stephen A. Sherwin received a grant of 2,567 restricted stock units. These RSUs give him the right to receive an equal number of Neurocrine common shares when they vest. According to the award terms, the RSUs will vest in full on May 27, 2027, and he will then receive 2,567 shares if he remains eligible under the plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SHERWIN STEPHEN A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	2,567	$0.00	--

Holdings After Transaction: Restriced Stock Unit — 2,567 shares (Direct, null)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs will vest in full on May 27, 2027.

Key Figures

RSUs granted: 2,567 units Underlying common shares: 2,567 shares Grant price: $0.0000 per unit +2 more

5 metrics

RSUs granted 2,567 units Restricted stock units awarded on May 27, 2026

Underlying common shares 2,567 shares Each RSU converts into one common share upon vesting

Grant price $0.0000 per unit Equity award with no cash exercise price

Post-award derivative holdings 2,567 units Total RSUs following the reported grant

Vesting date May 27, 2027 RSUs vest in full on this date

Key Terms

Restricted Stock Unit, RSU, vest in full, Form 4

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

vest in full financial

"The RSUs will vest in full on May 27, 2027."

Form 4 regulatory

"This Form 4 reports an equity award, not an open-market trade."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 06:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERWIN STEPHEN A

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restriced Stock Unit⁽¹⁾	$0	05/27/2026		A		2,567		⁽²⁾	⁽²⁾	Common Stock	2,567	$0	2,567	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX director Stephen Sherwin report?

Stephen A. Sherwin reported receiving 2,567 restricted stock units as an equity grant. Each RSU represents one share of Neurocrine Biosciences common stock, deliverable when the award vests according to its terms.

How many Neurocrine Biosciences (NBIX) RSUs were granted in this Form 4?

The Form 4 shows a grant of 2,567 restricted stock units to director Stephen A. Sherwin. These RSUs are a form of stock-based compensation that can convert into 2,567 common shares when they vest.

When do Stephen Sherwin’s NBIX restricted stock units vest?

The restricted stock units granted to Stephen A. Sherwin vest in full on May 27, 2027. On that vesting date, he is entitled to receive one share of Neurocrine common stock for each of the 2,567 RSUs.

Does this NBIX Form 4 show a stock purchase or sale?

This Form 4 reports an equity award, not an open-market trade. Stephen A. Sherwin acquired 2,567 restricted stock units as compensation, with no cash purchase price and no shares sold in the reported transaction.

What does each NBIX restricted stock unit represent in this filing?

Each restricted stock unit represents the right to receive one share of Neurocrine Biosciences common stock upon vesting. When the 2,567 RSUs vest on May 27, 2027, they will convert into 2,567 shares if conditions are met.